Home › Trials › NCT04766177
Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 3 to 12

Using Bumetanide to Treat Autism in Children

Official title: Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children

Run by Tanta University · NCT04766177 · Data updated 2026-11-12

This study is testing if Bumetanide can help reduce autism symptoms in children aged 3 to 12 years.

Quick facts

PhasePhase 3
Study typeInterventional
Ages3 Years to 12 Years
SexAll
Enrollment80 (estimated)
SponsorTanta University
Academic / other
Locations1 site (Tanta)
StatusRecruiting
StartedJanuary 1, 2021
Main results expectedDecember 1, 2030
Study endsDecember 1, 2030
Registry record updatedFebruary 23, 2021
Trial IDNCT04766177 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are children aged 3 to 12 years diagnosed with Autism Spectrum Disorder.

Probably not a fit

Patients with autism associated with neurological conditions, hepatic or renal dysfunction, or specific syndromes will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of Bumetanide, a diuretic, in treating children diagnosed with Autism Spectrum Disorder (ASD). It involves a Phase 3 interventional approach where participants aged 3 to 12 years will receive either Bumetanide or a placebo. The study aims to assess the impact of this medication on the symptoms of autism as measured by standardized scales. The trial will include children with a confirmed diagnosis of ASD while excluding those with certain neurological or medical conditions.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for managing symptoms of autism in children.

How similar studies have gone: While the use of Bumetanide in autism is a novel approach, there have been limited studies exploring its effects, making this trial particularly significant.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. All patients with ASD diagnosed by CARS rating Scale⩾30.
2. Age of patients range between (3-12) years.

Exclusion Criteria:

* Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).

Where it's running

  • Sherief Abd-Elsalam
    Tanta, Egypt     Recruiting

Study contacts

  • Principal investigator: Osama Elagamy, Prof — Pediatrics Department- Kafr-Elsheikh University
  • Study coordinator: Sherief Abd-Elsalam, ass. prof.
  • Email: sheriefabdelsalam@yahoo.com
  • Phone: 00201147773440

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Autism 558Tanta University 186
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.